Carsgen Therapeutics Holdings Limited is a biopharmaceutical company that focuses on innovative CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment. The company's primary aim is to... Carsgen Therapeutics Holdings Limited is a biopharmaceutical company that focuses on innovative CAR-T (Chimeric Antigen Receptor T-cell) therapies for cancer treatment. The company's primary aim is to develop groundbreaking therapeutic approaches to combat various types of hematological malignancies and solid tumors. By engineering T-cells to better recognize and attack cancer cells, Carsgen Therapeutics is at the forefront of immunotherapy, a sector poised to transform oncology treatment. The company's program pipeline includes advanced clinical trials and research initiatives targeting difficult-to-treat cancers. Headquartered in Shanghai, Carsgen leverages its strong research and development infrastructure to bring novel therapies from the laboratory to clinical practice. As a player in the biopharmaceutical industry, Carsgen Therapeutics contributes to the global effort in enhancing cancer treatment modalities and improving patient outcomes, thereby positioning itself as a significant participant in the rapidly evolving biotechnology sector.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by CARsgen Therapeutics Holdings

We reviewed CARsgen Therapeutics Holdings's website and available disclosure materials for the 2024 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review CARsgen Therapeutics Holdings's data?

Start your 30-day free trial to request a data review for CARsgen Therapeutics Holdings.

Start Free Trial

Legal Center Contact Us